<DOC>
	<DOCNO>NCT00245622</DOCNO>
	<brief_summary>This 1 year study evaluate efficacy , safety , tolerability Tovaxin T cell therapy subject clinically isolated syndrome ( CIS ) relapse-remitting multiple sclerosis ( RR-MS ) .</brief_summary>
	<brief_title>Autologous T Cell Vaccine ( TCV ) Multiple Sclerosis</brief_title>
	<detailed_description>A 2 arm , 52 week parallel-group Tovaxin versus placebo subject CIS RR-MS . Subjects provide write , informed consent complete screen procurement assessment provide blood use vaccine production . Eligible subject enrol receive either Tovaxin placebo complete baseline assessment . Randomization enrol subject receive study treatment subcutaneous injection week 0 , 4 , 8 , 12 , 24 . Subjects monitor CBC , serum chemistry , urinalysis , Expanded Disability Status Scale ( EDSS ) , MSFC , MSQLI , magnetic resonance imaging ( MRI ) , monitor myelin reactive T cell safety , efficacy , tolerability Tovaxin .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 55 year old Presence myelin reactive T cell screen Diagnosis CIS screen MRI fulfils Barkhof criterion dissemination space Diagnosis MS within past 10 year accord McDonald criterion ( 2005 ) Baseline EDSS score 0 5.5 inclusively Unable produce T cell vaccine Diseasemodifying treatment MS last 30 day 60 day steroidal treatment Diagnosis progressiverelapsing , secondary progressive , primary progressive MS Planned pregnancy , currently pregnant , breastfeed Any prior treatment total lymphoid irradiation , cladribine , T cell T cell receptor vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Phase 2b Tovaxin</keyword>
	<keyword>Clinically Isolated Syndrome ( CIS )</keyword>
	<keyword>Relapse-Remitting Multiple Sclerosis ( RR-MS )</keyword>
</DOC>